BridgeMD
Compares treatment options for Non-small Cell Lung Cancer (NSCLC)
Official title Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients
ClinicalTrials.gov ID: NCT06114108
What this study is testing
- What it's testing
- Unfortunately, most patients are already at a very advanced stage when they are diagnosed with lung cancer, i.e. the cancer has already spread outside the lungs forming metastases.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients fulfilling all of the following at screening may be enrolled in the trial.
- The are irrespective from the tumor burden at the time of primary diagnosis before initiation of first line systemic therapy. Treatment of brain...
- Adults (18 years or older)
- Tissue confirmed, pre-treatment clinical stage IV NSCLC
- ECOG performance status ≤ 1
You likely can't join if
- The presence of any one of the following exclusion criteria at screening will lead to exclusion of the participant:
- Serious concomitant disorder that would compromise patient safety during LAT
- Unresolved complications from initial systemic anticancer treatment, higher than CTCAE grade 2
- Metastatic locations such as malignant ascites, malignant pleural or malignant pericardial effusion, diffuse lymphangiosis of skin or lung, diffuse...
- Women who are pregnant or breast feeding
- Patient is currently involved in a trial that either does not permit participation in other trials or would result in excessive patient burden if...
See the full eligibility criteria
- Patients fulfilling all of the following at screening may be enrolled in the trial.
- The are irrespective from the tumor burden at the time of primary diagnosis before initiation of first line systemic therapy. Treatment of brain metastases upfront or after an induction phase of standard systemic...
- Adults (18 years or older)
- Tissue confirmed, pre-treatment clinical stage IV NSCLC
- ECOG performance status ≤ 1
- Patients responding after 3 cycles (4th bridging cycle up until randomization is allowed) or 3 months of first line SoC systemic therapy with PR or SD in restaging imaging, and presenting with (induced) oligometastatic...
- Patients may have up to 5 cranial metastases in addition to the oligoresidual extracranial metastases as long as they are amenable for radiotherapy or surgery.
- The primary tumor and all oligopersistent metastases must be amenable for radical LAT (surgery or radiotherapy)
- Patients of reproductive age agree to use double contraception during the study
- Patient is able to understand trial procedures and is able/willing to adhere to trial procedures as confirmed by signature
- The presence of any one of the following exclusion criteria at screening will lead to exclusion of the participant:
- Serious concomitant disorder that would compromise patient safety during LAT
- Unresolved complications from initial systemic anticancer treatment, higher than CTCAE grade 2
- Metastatic locations such as malignant ascites, malignant pleural or malignant pericardial effusion, diffuse lymphangiosis of skin or lung, diffuse bone marrow metastasis, abdominal masses/abdominal organomegaly...
- Women who are pregnant or breast feeding
- Patient is currently involved in a trial that either does not permit participation in other trials or would result in excessive patient burden if another trial were joined. In such cases, the co-investigators' team and...
The study team makes the final eligibility decision.
Where it's taking place
- Aarau, Switzerland
- Bellinzona, Switzerland
- Chur, Switzerland
- Fribourg, Switzerland
- Geneva, Switzerland
- Lucerne, Switzerland
- Zurich, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aarau, Switzerland; Bellinzona, Switzerland; Chur, Switzerland; Fribourg, Switzerland; Geneva, Switzerland; Lucerne, Switzerland and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.